MARKET

RARE

RARE

Ultragenyx
NASDAQ

Real-time Quotes | Nasdaq Last Sale

44.22
-0.54
-1.21%
After Hours: 44.49 +0.27 +0.60% 16:11 09/17 EDT
OPEN
44.23
PREV CLOSE
44.76
HIGH
45.57
LOW
43.98
VOLUME
439.07K
TURNOVER
--
52 WEEK HIGH
90.98
52 WEEK LOW
37.44
MARKET CAP
2.55B
P/E (TTM)
-6.3099
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of RARE and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 19 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

RARE News

  • Ultragenyx Pharmaceutical Inc (RARE) President & CEO Emil D Kakkis Bought $218,150 of Shares
  • GuruFocus.com.6d ago
  • Ultragenyx to Submit sBLA for Label Expansion of Crysvita
  • Zacks.6d ago
  • Ultragenyx to file U.S. application for expanded use of Crysvita
  • seekingalpha.09/10 18:28
  • Ultragenyx and Kyowa Kirin Announce Intent to Submit Supplemental Biologics License Application to U.S. FDA for Crysvita® (burosumab) in Tumor-Induced Osteomalacia (TIO)
  • GlobeNewswire.09/10 14:00

More

Industry

Biotechnology & Medical Research
-0.22%
Pharmaceuticals & Medical Research
+0.42%

Hot Stocks

Name
Price
%Change

About RARE

Ultragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies. Its product candidates under biologics category include KRN23 (UX023) and recombinant human beta-glucuronidase (rhGUS) (UX003). Its product candidates under small-molecule category include UX007 and aceneuramic acid extended-release (Ace-ER) (UX001). It is also developing recombinant human protective protein cathepsin-A (rhPPCA). KRN23 is a fully human monoclonal antibody. rhGUS is an intravenous (IV) enzyme replacement therapy. UX007 is a substrate replacement therapy. It is developing Ace-ER for the treatment of GNE myopathy. rhPPCA is in preclinical development.
More

Webull offers Ultragenyx Pharmaceutical Inc (RARE) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.